Dr. Jacobson
As an academic researcher, Dr. Jacobson studied the molecular basis of autoimmunity and the use of cDNA vaccines as a means to break peripheral tolerance. In early-stage biotech, he led initiatives on IND‑enabling studies for therapeutic cancer vaccines and oversaw relationships with contract manufacturing organizations (CMO). As a consultant, he performed process validation/scale-up activities at a CMO for an oligonucleotide-based adjuvant, and, at large pharma, he was on a team that was responsible for the process development of a quadrivalent influenza vaccine. Currently, he focuses on providing advice on the quality and regulatory requirements for vaccine manufacturing and application submissions. On a personal level, he is an engaging raconteur.